ReviewGastroenterology report2026
Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era.
Review in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric or gastroesophageal junction cancer (GC/GEJC) ranks as the fifth leading cause of cancer-related mortality worldwide. Curative-intent surgery remains the cornerstone of treatment for locally advanced GC/GEJC. However, a substantial proportion of patients still experience disease recurrence even after complete resection. Based on the pivotal results of the FLOT4 and ESOPEC trials, perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been established as the standard of care for patients with locally advanced upper gastrointestinal tract adenocarcinoma, including GC/GEJC, in Western countries, whereas surgery followed by adjuvant chemotherapy remains the standard in Asia. The positive findings from the PRODIGY and RESOLVE trials have further supported neoadjuvant and perioperative strategies in Asia, fostering a trend toward global harmonization. Following the first global collaboration in KEYNOTE-585, the randomized phase III MATTERHORN trial represented a major milestone by demonstrating, for the first time, a significant improvement in event-free survival and overall survival with the addition of durvalumab to perioperative FLOT. This provided the first global phase III evidence supporting the integration of immune checkpoint inhibitors with perioperative chemotherapy in GC/GEJC. In this review, we spotlight the paradigm shift in perioperative treatment and address challenges associated with implementing FLOT plus durvalumab in daily practice. We also discuss future therapeutic directions, including molecularly targeted therapies and novel multimodal approaches. The MATTERHORN trial has set the global stage for advancing the management of resectable GC/GEJC, heralding the beginning of a new era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.